Zacks Investment Research on MSN
JNJ's nipocalimab meets goal in phase II study for systemic lupus
Johnson & Johnson JNJ announced that the phase IIb JASMINE study, which evaluated its pipeline candidate, nipocalimab, for treating adult patients with systemic lupus erythematosus (SLE), has met the ...
Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease ...
TEL AVIV, Israel, Feb. 21, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results